Please login to the form below

Not currently logged in
Email:
Password:

finerenone

This page shows the latest finerenone news and features for those working in and with pharma, biotech and healthcare.

Xarelto and Eylea continue to dominate Bayer's pharma sales

Xarelto and Eylea continue to dominate Bayer's pharma sales

They include five candidates in phase III trials: copanlisib for non-Hodgkin lymphoma, ODM-201 for hormone-sensitive prostate cancer, finerenone for diabetic kidney disease, vilaprisan for uterine fibroids and endriametosis

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Bayer recently started three late-stage trials of its HF candidate finerenone - a mineralocorticoid drug designed as a safer replacement for older drugs in the class such as eplerenone and spironolactone,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics